We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Expanded Genetic Testing Leads to Additional Cardiomyopathy, Arrhythmia Diagnoses

By LabMedica International staff writers
Posted on 17 Aug 2022

Genetic testing for nonischemic cardiomyopathies and inherited arrhythmias is recommended by cardiovascular societies to establish a genetic diagnosis, guide clinical management, and identify family members at risk. More...

However, many individuals with cardiomyopathies or arrhythmias do not receive genetic testing and therefore cannot benefit from gene-specific clinical management. Barriers to testing include limited clinician knowledge of genetics and results interpretation as well as real and perceived concerns regarding cost, insurance coverage, and low diagnostic yields.

Medical Scientists at the Feinberg School of Medicine (Chicago, IL, USA) and their colleagues performed a cohort study that involved a retrospective review of DNA sequencing results for cardiomyopathy- and arrhythmia-associated genes. The study included 4,782 patients with a suspected genetic cardiomyopathy or arrhythmia who were referred for genetic testing by 1,203 clinicians; all patients participated in a no-charge, sponsored genetic testing program for cases of suspected genetic cardiomyopathy and arrhythmia at a single testing site from July 12, 2019, through July 9, 2020.

Next-generation sequencing gene panels were used to simultaneously test for both sequence and exon-level copy number variants. Up to 150 genes associated with cardiomyopathies or arrhythmias were sequenced. The primary panel included 67 genes with established associations with cardiomyopathies and arrhythmias. Four optional add-on panels that included genes with preliminary associations with cardiomyopathies and arrhythmias could be ordered initially or after receipt of initial results without charge. Each gene was targeted with oligonucleotide baits (Agilent Technologies, Santa Clara, CA, USA; Roche, Pleasanton, CA, USA; Integrated DNA Technologies, Coralville, IA, USA) that were designed to capture exons and 10 bases of flanking intronic sequences.

The investigators reported that among 4,782 patients (mean age, 40.5± 21.3 years; 2,551 male [53.3%]) who received genetic testing, a positive result (molecular diagnosis) was confirmed in 954 of 4,782 patients (19.9%). Of those, 630 patients with positive results (66.0%) had the potential to inform clinical management associated with adverse clinical outcomes, increased arrhythmia risk, or targeted therapies. Combined cardiomyopathy and arrhythmia gene panel testing identified clinically relevant variants for 15 patients suspected of having a genetic cardiomyopathy or arrhythmia. If only patients with a high suspicion of genetic cardiomyopathy or arrhythmia had been tested, at least 137 positive results (14.4%) would have been missed.

If testing had been restricted to panels associated with the clinician-provided diagnostic indications, 75/689 positive results (10.9%) would have been missed; 27/75 findings (36.0%) gained through combined testing involved a cardiomyopathy indication with an arrhythmia genetic finding or vice versa. Cascade testing of family members yielded 402 of 958 positive results (42.0%). Patients referred for arrhythmogenic cardiomyopathy had the lowest rate of variants of uncertain significance (81/176 patients [46.0%]), and patients referred for catecholaminergic polymorphic ventricular tachycardia had the highest rate (48/76 patients [63.2%]).

Elizabeth M. McNally, MD, PhD, Professor of Genetic Medicine and senior author of the study said, “Notably, this study found a 10.9% gain in genetic diagnoses that would have been missed if testing had been limited to genes associated with a single cardiomyopathy or arrhythmia subtype.”

The authors concluded that comprehensive genetic testing for cardiomyopathies and arrhythmias revealed diagnoses that would have been missed by disease-specific testing. In addition, comprehensive testing provided diagnostic and prognostic information that could have potentially changed management and monitoring strategies for patients and their family members. They added that the benefits of identifying additional cases outweighs the risks posed by detecting variants of uncertain significance, which were found in 51.2% of their cohort. The study was published on August 10, 2022 in the journal JAMA Cardiology.

Related Links:
Feinberg School of Medicine 
Agilent Technologies 
Roche
Integrated DNA Technologies 


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.